Phase 2, single-arm, 26 week trial of eculizumab evaluating time to haematologic and renal improvements in atypical haemolytic uraemic syndrome patients aged 12 years and above with chronic kidney disease.

Trial Profile

Phase 2, single-arm, 26 week trial of eculizumab evaluating time to haematologic and renal improvements in atypical haemolytic uraemic syndrome patients aged 12 years and above with chronic kidney disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2014

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top